Related Experiment Video
Updated: Jun 26, 2025
09:38
Comprehensive Analysis of Drug Response using the FLICK Assay
Published on: June 6, 2025
59
Exposure-Response Analyses for Belzutifan to Inform Dosing Considerations and Labeling
Dhananjay D Marathe1, Petra M Jauslin2, Huub Jan Kleijn2
1Merck & Co., Inc., Rahway, NJ, USA.
Journal of Clinical Pharmacology
|May 16, 2024
Summary
Belzutifan effectively treats von Hippel-Lindau disease-associated cancers. Exposure-response analyses confirmed its benefit-risk profile, supporting the 120 mg daily dose without needing adjustments for specific patient groups.
Area of Science:
- Pharmacology and Oncology
- Clinical Trial Analysis
- Drug Development
Background:
- Belzutifan is an oral hypoxia-inducible factor-2α inhibitor approved for von Hippel-Lindau (VHL) disease-associated renal cell carcinoma (RCC) and other neoplasms.
- Clinical studies evaluated belzutifan's safety and efficacy in solid tumors, RCC, and VHL-RCC.
Purpose of the Study:
- To conduct exposure-response (E-R) analyses for belzutifan's efficacy and safety endpoints.
- To evaluate relationships between belzutifan exposure, efficacy outcomes, safety events, and pharmacodynamic biomarkers.
Main Methods:
- Population pharmacokinetic modeling to estimate belzutifan exposures.
- Regression techniques and time-to-event analyses for E-R assessments.
- Evaluation of efficacy (response rates, PFS), safety (anemia, hypoxia), and biomarkers (EPO, Hgb).
Main Results:
- Efficacy E-R analyses showed generally flat relationships with non-significant positive trends.
- Safety E-R indicated no relationship with hypoxia but a positive relationship with anemia, influenced by baseline hemoglobin.
- Exposure-dependent reductions in erythropoietin (EPO) and hemoglobin (Hgb) were observed.
Conclusions:
- Belzutifan's benefit-risk profile supports the 120 mg once-daily dose for VHL disease-associated neoplasms.
- No a priori dose adjustments are recommended for any subpopulation based on E-R analyses.
- These findings support belzutifan's labeling and overall development program.
Related Concept Videos
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
125
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
125
01:22Dose-Response Relationship: Potency and Efficacy
4.4K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.4K
01:03Dose-Response Relationship: Overview
3.1K
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
3.1K
01:19Pharmacovigilance
826
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
826
01:25Dose-Response Relationship: Selectivity and Specificity
6.7K
Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and...
6.7K
01:21Factors Affecting Drug Response: Overview
2.0K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.0K